Abstract:
Dexlansoprazole, an enantiomer of Lansoprazole, is a proton pump inhibitor, which
irreversibly blocks the hydrogen/potassium adenosine triphosphatase enzyme system (the
H+/K + ATPase, or more commonly just gastric proton pump) of the gastric parietal cell.
The purpose of this study is to analyze the market feasibility study of Dexlansoprazole
and to launch Dexlansoprazole in Bangladesh pharma market. Many books, journals,
articles were also used to know efficacy and safety profile of drugs. International Market
Strategy (IMS) data was used to determine the market size. Dexlansoprazole gives
prolonged action which is almost double than Lansoprazole. It shows better efficacy in
erosive oesophagitis, GERD, NERD than the other proton pump inhibitor. Therefore, the
total market size of Dexlansoprazole will be increased and it will capture the
Rabeprazole, Esomeprazole and Pantoprazole. The estimated market size for
Dexlansoprazole is 11.0 crore taka and the estimated growth rate for Dexlansoprazole is
10-12% in the next year. So it is better to launch Dexlansoprazole in the next year.
Description:
This thesis submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy (B.Pharm) in East West University, Dhaka, Bangladesh.
